Common treatment of certain autoimmune disease does not appear effective

Among patients with the systemic autoimmune disease primary Sjögren syndrome, use of hydroxychloroquine, the most frequently prescribed treatment for the disorder, did not improve symptoms during 24 weeks of treatment compared with placebo, according to a study in the July 16 issue of JAMA.

Primary Sjögren is characterized by mouth and eye dryness, pain, and fatigue, with systemic manifestations occurring in approximately one-third of . Despite the wide use of in clinical practice, evidence regarding its efficacy is limited, according to background information in the article.

Jacques-Eric Gottenberg, M.D., Ph.D., of the Universite de Strasbourg, Strasbourg, France, and colleagues randomly assigned 120 patients with primary Sjögren syndrome to receive hydroxychloroquine or placebo for 24 weeks. All patients (treatment and placebo) were prescribed hydroxychloroquine between weeks 24 and 48. The study was conducted at 15 university hospitals in France.

At 24 weeks, the proportion of patients meeting the primary end point (30 percent or greater reduction in 2 of 3 scores evaluating dryness, pain, and fatigue) was 17.9 percent (10/56) in the hydroxychloroquine group and 17.2 percent (11/64) in the . Use of hydroxychloroquine was also not associated with improvement in certain lab tests used to monitor the activity of Sjögren (anti-SSA antibodies, IgG levels). During the first 24 weeks, there were 2 serious adverse events in the hydroxychloroquine group and 3 in the placebo group. In the last 24 weeks, there were 3 in the hydroxychloroquine group and 4 in the placebo group.

"In the present study, hydroxychloroquine did not demonstrate efficacy for the main disabling symptoms—dryness, pain, and fatigue—of primary Sjögren syndrome compared with . [This trial] extends the negative results of the only previous controlled crossover trial, which included 19 patients and confirms that previous open trials might have overestimated the of hydroxychloroquine in primary Sjögren syndrome," the authors write.

"Further studies are needed to evaluate longer-term outcomes."

More information: DOI: 10.1001/jama.2014.7682

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Sierra Leone bans Christmas parties amid Ebola

10 hours ago

Alice Marke and her family aren't celebrating Christmas the way they used to: The deadly Ebola epidemic in Sierra Leone means no festive parties at the beach, no carolers singing at night.

Fourth UN staff contracts Ebola in Liberia

12 hours ago

A fourth member of the UN mission in Liberia, the country hardest-hit by the Ebola epidemic, has been hospitalised after testing positive for the virus.

Tuberculosis avoids and subverts host immunity

Dec 23, 2014

An ancient disease, tuberculosis (TB) continues to be one of the major causes of disability and death worldwide. The recent TB cases in Quebec among the Inuit community has underscored the need to find new avenues to eradicate ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.